PDCD1 and cancer: Similarly, Gorgulho et al. demonstrated that low levels of sBTLA post therapy associated with improved OS at both an early (p = 0.018) and late (p = 0.009) time point in patients with a variety of cancers who were treated with anti-PD-1, combination therapy (of anti-PD-1 plus anti-CTLA4) or other ICI (Table S3) [83].